Strong PhII data in triglyceride reduction attracts partners to Essentialis
This article was originally published in Scrip
Executive Summary
Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.
You may also be interested in...
Capina, Essentialis Merger To Create Rare Disease Firm
The combined company would advance a diazoxide choline controlled-release daily pill for treating patients with Prader-Willi syndrome through pivotal Phase II/III clinical trialing.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.